Parkinsonian Disorders [clinicaltrials_resource:d2d36a086f81ea8e74a710e1a5cd301a]
Sedation During Microelectrode Recordings Before Deep Brain Stimulation for Movement Disorders. [clinicaltrials:NCT00355927]Study of Preladenant for the Treatment of Antipsychotic Induced Movement Disorders in Subjects With Schizophrenia (Study P04628)(TERMINATED) [clinicaltrials:NCT00686699]Usefulness of α-synuclein as a Marker for Early Diagnosis of Parkinson's Disease in Skin Biopsy. [clinicaltrials:NCT01380899]Evaluation of the Efficacy and Safety of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias [clinicaltrials:NCT01385592]Evaluation of the Efficacy and Safety of Modified Release AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias [clinicaltrials:NCT01491529]Open-label, Long-term Safety Extension Study of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias [clinicaltrials:NCT01491932]Effect of Undenatured Cysteine-Rich Whey Protein Isolate (HMS 90®) in Patients With Parkinson's Disease [clinicaltrials:NCT01662414]Repetitive Transcranial Magnetic Stimulation for Freezing of Gait [clinicaltrials:NCT01853150]
condition [clinicaltrials_vocabulary:condition]
Brain Study of Patients With Frontal Lobe Dementia and Parkinsonian Disorders [clinicaltrials:NCT00001178]The Association of Neurotoxin Exposure With Parkinson's Disease and Parkinsonism in World War II Veterans and Other Men [clinicaltrials:NCT00018577]Treatment of Agitation/Psychosis in Dementia/Parkinsonism (TAP/DAP) [clinicaltrials:NCT00043849]Risperidone and Olanzapine for the Schizophrenic Patients With Neuroleptic-Induced Acute Dystonia or Parkinsonism [clinicaltrials:NCT00331825]Sedation During Microelectrode Recordings Before Deep Brain Stimulation for Movement Disorders. [clinicaltrials:NCT00355927]Transcranial Duplex Scanning and Single Photon Emission Computer Tomography (SPECT) in Parkinsonian Syndromes [clinicaltrials:NCT00368199]Effects of Coenzyme Q10 in Progressive Supranuclear Palsy (PSP) [clinicaltrials:NCT00382824]clinicaltrials:NCT00382967Low Dose Apomorphine and Parkinsonism [clinicaltrials:NCT00472355]clinicaltrials:NCT00682513Study of Preladenant for the Treatment of Antipsychotic Induced Movement Disorders in Subjects With Schizophrenia (Study P04628)(TERMINATED) [clinicaltrials:NCT00686699]clinicaltrials:NCT00745030Botulinum Toxin for Treatment of Seborrhic Dermatitis in Parkinsonian Patients [clinicaltrials:NCT00767546]Acute Effects of Preladenant (SCH 420814) on Dyskinesia and Parkinsonism in Levodopa Treated Participants (P05550) [clinicaltrials:NCT00845000]Amantadine for Improving Neurologic Symptoms in Ataxia-Telangiectasia [clinicaltrials:NCT00950196]Davunetide (AL-108) in Predicted Tauopathies - Pilot Study [clinicaltrials:NCT01056965]Repetitive Transcranial Magnetic Stimulation (TMS) for Progressive Supranuclear Palsy and Corticobasal Degeneration [clinicaltrials:NCT01174771]Exploratory Study Using Nanotechnology to Detect Biomarkers of Parkinson's Disease From Exhaled Breath [clinicaltrials:NCT01246336]Parkinson's Disease, Diagnostic Observations (PADDO) [clinicaltrials:NCT01249768]Molecular Analysis of Human Neural Stem Cells [clinicaltrials:NCT01329926]Detecting Dopaminergic Deficits in Individuals At-risk for Parkinsonism [clinicaltrials:NCT01358474]Usefulness of α-synuclein as a Marker for Early Diagnosis of Parkinson's Disease in Skin Biopsy. [clinicaltrials:NCT01380899]Evaluation of the Efficacy and Safety of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias [clinicaltrials:NCT01385592]DaTSCAN Imaging in Aging and Neurodegenerative Disease [clinicaltrials:NCT01453127]Providing Specialty Care to Individuals With Parkinsonism Directly in Their Homes Via Web-based Video Conferencing— A Comparative Effectiveness Study [clinicaltrials:NCT01476306]Evaluation of the Efficacy and Safety of Modified Release AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias [clinicaltrials:NCT01491529]Open-label, Long-term Safety Extension Study of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias [clinicaltrials:NCT01491932]MRI Study of Brain Activity in Healthy Adults and Individuals With Parkinsonism and Rapid Eye Movement Disorder. [clinicaltrials:NCT01547481]A Trial of 18F-AV-133 Positron Emission Tomography (PET) Imaging to Differentiate Subjects With Parkinson's Disease (PD) From Other Movement Disorders [clinicaltrials:NCT01550484]Incobotulinum Toxin A (Xeomin®) for Troublesome Sialorrhea in Parkinson's Disease (PD)/Parkinsonism and Amyotrophic Lateral Sclerosis (ALS) [clinicaltrials:NCT01565395]Mobilaser Study to Help With People Who Are Having Problems With Their Gait [clinicaltrials:NCT01581645]Incobotulinum Toxin A (Xeomin®) for Troublesome Sialorrhea in Parkinson's Disease (PD)/Parkinsonism [clinicaltrials:NCT01653132]Effect of Undenatured Cysteine-Rich Whey Protein Isolate (HMS 90®) in Patients With Parkinson's Disease [clinicaltrials:NCT01662414]Development of a Novel 18F-DTBZ PET Imaging as a Biomarker to Monitor Neurodegeneration of PARK6 and PARK8 Parkinsonism [clinicaltrials:NCT01759888]The Differential Diagnosis of Parkinson's Disease and Parkinsonism by Positron-emission Tomography [clinicaltrials:NCT01824056]Repetitive Transcranial Magnetic Stimulation for Freezing of Gait [clinicaltrials:NCT01853150]Evaluation of Safety and Tolerability of Fetal Mesencephalic Dopamine Neuronal Precursor Cells for Parkinson's Disease [clinicaltrials:NCT01860794]Identifying Biomarkers of Parkinson's Disease Using Magnetic Resonance Imaging (MRI) [clinicaltrials:NCT01888185]Parkinsonism in Spinocerebellar Ataxia Type 6 [clinicaltrials:NCT01934998]Establishment of Clinical Basis for Hematopoietic Growth Factors Therapy in Brain Injury [clinicaltrials:NCT02018406]
condition browse [clinicaltrials_vocabulary:condition-browse]
Brain Study of Patients With Frontal Lobe Dementia and Parkinsonian Disorders [clinicaltrials:NCT00001178]The Association of Neurotoxin Exposure With Parkinson's Disease and Parkinsonism in World War II Veterans and Other Men [clinicaltrials:NCT00018577]Treatment of Agitation/Psychosis in Dementia/Parkinsonism (TAP/DAP) [clinicaltrials:NCT00043849]Risperidone and Olanzapine for the Schizophrenic Patients With Neuroleptic-Induced Acute Dystonia or Parkinsonism [clinicaltrials:NCT00331825]Sedation During Microelectrode Recordings Before Deep Brain Stimulation for Movement Disorders. [clinicaltrials:NCT00355927]Transcranial Duplex Scanning and Single Photon Emission Computer Tomography (SPECT) in Parkinsonian Syndromes [clinicaltrials:NCT00368199]Effects of Coenzyme Q10 in Progressive Supranuclear Palsy (PSP) [clinicaltrials:NCT00382824]clinicaltrials:NCT00382967Low Dose Apomorphine and Parkinsonism [clinicaltrials:NCT00472355]clinicaltrials:NCT00682513Study of Preladenant for the Treatment of Antipsychotic Induced Movement Disorders in Subjects With Schizophrenia (Study P04628)(TERMINATED) [clinicaltrials:NCT00686699]clinicaltrials:NCT00745030Botulinum Toxin for Treatment of Seborrhic Dermatitis in Parkinsonian Patients [clinicaltrials:NCT00767546]Acute Effects of Preladenant (SCH 420814) on Dyskinesia and Parkinsonism in Levodopa Treated Participants (P05550) [clinicaltrials:NCT00845000]Amantadine for Improving Neurologic Symptoms in Ataxia-Telangiectasia [clinicaltrials:NCT00950196]Davunetide (AL-108) in Predicted Tauopathies - Pilot Study [clinicaltrials:NCT01056965]Repetitive Transcranial Magnetic Stimulation (TMS) for Progressive Supranuclear Palsy and Corticobasal Degeneration [clinicaltrials:NCT01174771]Exploratory Study Using Nanotechnology to Detect Biomarkers of Parkinson's Disease From Exhaled Breath [clinicaltrials:NCT01246336]Parkinson's Disease, Diagnostic Observations (PADDO) [clinicaltrials:NCT01249768]Molecular Analysis of Human Neural Stem Cells [clinicaltrials:NCT01329926]Detecting Dopaminergic Deficits in Individuals At-risk for Parkinsonism [clinicaltrials:NCT01358474]Usefulness of α-synuclein as a Marker for Early Diagnosis of Parkinson's Disease in Skin Biopsy. [clinicaltrials:NCT01380899]Evaluation of the Efficacy and Safety of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias [clinicaltrials:NCT01385592]DaTSCAN Imaging in Aging and Neurodegenerative Disease [clinicaltrials:NCT01453127]Providing Specialty Care to Individuals With Parkinsonism Directly in Their Homes Via Web-based Video Conferencing— A Comparative Effectiveness Study [clinicaltrials:NCT01476306]Evaluation of the Efficacy and Safety of Modified Release AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias [clinicaltrials:NCT01491529]Open-label, Long-term Safety Extension Study of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias [clinicaltrials:NCT01491932]MRI Study of Brain Activity in Healthy Adults and Individuals With Parkinsonism and Rapid Eye Movement Disorder. [clinicaltrials:NCT01547481]A Trial of 18F-AV-133 Positron Emission Tomography (PET) Imaging to Differentiate Subjects With Parkinson's Disease (PD) From Other Movement Disorders [clinicaltrials:NCT01550484]Incobotulinum Toxin A (Xeomin®) for Troublesome Sialorrhea in Parkinson's Disease (PD)/Parkinsonism and Amyotrophic Lateral Sclerosis (ALS) [clinicaltrials:NCT01565395]Mobilaser Study to Help With People Who Are Having Problems With Their Gait [clinicaltrials:NCT01581645]Incobotulinum Toxin A (Xeomin®) for Troublesome Sialorrhea in Parkinson's Disease (PD)/Parkinsonism [clinicaltrials:NCT01653132]Effect of Undenatured Cysteine-Rich Whey Protein Isolate (HMS 90®) in Patients With Parkinson's Disease [clinicaltrials:NCT01662414]Development of a Novel 18F-DTBZ PET Imaging as a Biomarker to Monitor Neurodegeneration of PARK6 and PARK8 Parkinsonism [clinicaltrials:NCT01759888]The Differential Diagnosis of Parkinson's Disease and Parkinsonism by Positron-emission Tomography [clinicaltrials:NCT01824056]Repetitive Transcranial Magnetic Stimulation for Freezing of Gait [clinicaltrials:NCT01853150]Evaluation of Safety and Tolerability of Fetal Mesencephalic Dopamine Neuronal Precursor Cells for Parkinson's Disease [clinicaltrials:NCT01860794]Identifying Biomarkers of Parkinson's Disease Using Magnetic Resonance Imaging (MRI) [clinicaltrials:NCT01888185]Parkinsonism in Spinocerebellar Ataxia Type 6 [clinicaltrials:NCT01934998]Establishment of Clinical Basis for Hematopoietic Growth Factors Therapy in Brain Injury [clinicaltrials:NCT02018406]
condition mesh [clinicaltrials_vocabulary:condition-mesh]
Parkinsonian Disorders [clinicaltrials_resource:d2d36a086f81ea8e74a710e1a5cd301a]
Bio2RDF identifier
d2d36a086f81ea8e74a710e1a5cd301a
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:d2d36a086f81ea8e74a710e1a5cd301a
identifier
clinicaltrials_resource:d2d36a086f81ea8e74a710e1a5cd301a
title
Parkinsonian Disorders
@en
type
label
Parkinsonian Disorders [clinicaltrials_resource:d2d36a086f81ea8e74a710e1a5cd301a]
@en
Parkinsonian Disorders